The global renal biomarker market is predicted to be valued at US$ 1,541.2 million by 2024. The market valuation is estimated to be US$ 3,031.8 million by 2034, projected at a CAGR of 7%. Rise in the prevalence of chronic kidney diseases (CKD) globally propels the demand for biomarker-based diagnostic solutions to facilitate early detection and intervention. The rising awareness about the importance of kidney health and the growing burden of diabetes and hypertension contribute to the expanding market.
Advancements in biomarker discovery technologies, such as omics approaches and high-throughput screening, accelerate the identification of novel biomarkers, enhancing diagnostic accuracy and clinical utility. Variability in biomarker expression among patient populations and disease stages poses challenges to the standardization and reproducibility of biomarker assays, limiting their clinical utility.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1731
Regulatory hurdles and reimbursement complexities hinder market penetration and commercialization of biomarker tests. The high cost of biomarker development, validation, and commercialization, coupled with the long and uncertain regulatory approval process, presents barriers to entry for smaller companies and startups.
The renal biomarker market presents significant opportunities for growth and innovation. Technological advancements in biomarker discovery, such as artificial intelligence (AI) and machine learning, offer new avenues for biomarker identification, validation, and interpretation. The emphasis on preventive healthcare and population health management creates a demand for biomarker-based risk stratification tools to identify high-risk individuals and implement early interventions, driving market expansion.
Key Takeaways from the Market Study:
- By biomarker type, the functional biomarker is accounted to hold a market share of 54.9% in 2024.
- The United States is expected to register at a CAGR of 7.8% by 2034.
- The United Kingdom registers significant growth, projected at a CAGR of 8.5% by 2034.
- Based on diagnostic technique, the enzyme linked immunosorbent assay segment is accounted to hold a market share of 46.7% in 2024.
“The rising demand for biomarker-based diagnostic solutions to address the escalating CKD epidemic propels market growth, as healthcare providers prioritize preventive measures and proactive management of kidney health,” comments a Future Market Insights analyst.
Click for Methodology Details: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1731
Competitive Landscape:
Multinational corporations, biotechnology firms, and academic institutions characterize the competitive landscape of the renal biomarker market.
Lucrative key players dominate the market with their innovative biomarker assays and extensive research expertise, driving market competition and innovation.
Some of the key developments are:
- In November 2022, Revelation Biosciences Inc. announced the results of a recent exploratory biomarker analysis, unveiling clinical development plans for REVTx-300 in treating chronic kidney disease (CKD) and acute kidney injury (AKI).
- In 2023, Siemens Healthineers AG made a significant advancement in the renal biomarker market by introducing a novel biomarker panel to improve the diagnosis and management of renal diseases.
Key Companies Profiled:
- Abbott Laboratories
- BioPorto Diagnostics AS
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Nexelis (Pacific Biomarkers)
- BioMérieux
- Sphingotec GmbH
- Randox Laboratories Ltd
- Siemens Healthineers AG
- Beckman Coulter Inc. (Danaher Corporation)
- Bio-Rad Laboratories Inc.
Key Segments:
By Biomarker:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-regulated Proteins
- Neutrophil Gelatinase-Associated Lipocalin
- Kidney Injury Molecule-1
- Interleukin-18
- Others
By Diagnostic Technique:
- Enzyme Linked Immunosorbent Assay (ELISA)
- Particle-Enhanced Turbidimetric Immunoassay (PETIA)
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay (CLIA)
- Liquid Chromatography-Mass Spectrometry (LS-MS)
By End User:
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
- Hospitals
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- South Asia and Pacific
- East Asia
- The Middle East and Africa
Direct Purchase of this Report: https://www.futuremarketinsights.com/checkout/1731
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube